New Reference: Neoadjuvant FOLFOX + Panitumumab for Colon Cancer

  • Study

    Randomised, open-label, embedded phase II trial (FOxTROT)
    Resectable, locally advanced colon adenocarcinoma (T3-4, N0-2, M0) in RAS/BRAF-wildtype patients
    Neoadjuvant FOLFOX + panitumumab vs. FOLFOX alone

  • Efficacy

    Time to Recurrence events: 12% vs. 21% (HR: 0.51 [0.24-1.10])
    mDFS: HR: 0.51 [0.27-0.97]
    mOS: HR: 0.36 [0.16-0.85]
    TTR in EREG/AREG-high group: 11.9% vs. 25.0% (HR: 0.29 [0.09-0.99])

  • Safety

    Grade ≥3 AEs: diarrhea (8% vs. 3%), rash (22% vs. 2%)
    Perioperative complications (panitumumab vs. control): anastomotic leak, abscesses, wound infections, pneumonia (increased numerically)


    • Ann Oncol 2025;36:278-89

    Seligmann JF,Morton D,Elliott F Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population

    http://doi.org/10.1016/j.annonc.2024.12.013

    Reviewed by Ulas D. Bayraktar, MD on May 5, 2025

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag